Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;51(10):1391-1395.
doi: 10.1111/cea.13974. Epub 2021 Jul 5.

Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study

Douglas T Johnston  1 , Paula J Busse  2 , Marc A Riedl  3 , Marcus Maurer  4 , John Anderson  5 , Christina Nurse  6 , Neil Inhaber  6 , Ming Yu  6 , Aleena Banerji  7 ; HELP Study Investigators
Collaborators, Affiliations

Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study

Douglas T Johnston et al. Clin Exp Allergy. 2021 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

DTJ has received consulting/speaker fees from CSL Behring, Pharming and Shire (a Takeda company); and consulting fees from BioCryst and Regenxbio. PJB reports grants from Shire (a Takeda company); a lecture honorarium from CVS Health; and consulting fees from BioCryst, CSL Behring, Pearl Therapeutics, Pharming and Shire (a Takeda company). MAR has received research grants from BioCryst, CSL Behring, Pharming and Shire (a Takeda company); consulting fees from Adverum, Attune, BioCryst, CSL Behring, KalVista, Pharming, Pharvaris and Shire (a Takeda company); speaker honoraria from CSL Behring, Pharming and Shire; and is a medical advisory board member of the US Hereditary Angioedema Association. MM has received research grant support and/or speaker/consultancy fees from Adverum, Attune, BioCryst, CSL Behring, KalVista, Pharming, Pharvaris and Shire (a Takeda company). JA is a speaker bureau member for CSL Behring, Pharming, Biocryst and Shire (a Takeda company); has received consultancy fees from CSL Behring, Pharming and Shire (a Takeda company); and is a clinical trial investigator for Pharming, KalVista, BioCryst, CSL Behring and Shire (a Takeda company). CN, NI and MY are full‐time employees of Takeda Pharmaceutical Company Limited and hold stock/stock options in Takeda. AB has received institutional research/study support from BioCryst and Shire (a Takeda company) and/or honoraria for consulting from BioCryst, CSL Behring, KalVista, Pharming, Pharvaris and Shire (a Takeda company).

Figures

FIGURE 1
FIGURE 1
Reduction in baseline‐adjusted HAE attack rate vs. placebo during the overall treatment period (days 0–182) by subgroup. N for each overall subgroup category includes patients who received placebo. Mean (95% CI) rate ratios versus placebo are shown for each subgroup. *p < .05; **p < .001. HAE, hereditary angioedema; NE, not estimable; q2w, every 2 weeks; q4w, every 4 weeks
FIGURE 2
FIGURE 2
Reduction in HAE attack rate versus placebo for patients who received lanadelumab (150 mg q4w, 300 mg q4w or 300 mg q2w treatment groups combined) during days 0–69 (A) and during steady state (days 70–182) (B) by subgroup. N for each overall subgroup category includes patients who received placebo. Mean (95% CI) rate ratios vs. placebo are shown for each subgroup. *p < .05; **p < .001; ***the ratio was not estimable in the prior LTP oral and C1‐INH + oral subgroups because of the sparseness of the data. BMI, body mass index; C1‐INH, C1‐inhibitor; HAE, hereditary angioedema; LTP, long‐term prophylaxis; mo, month; NE, not estimable; q2w, every 2 weeks; q4w, every 4 weeks.
See this image and copyright information in PMC

References

    1. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—the 2017 revision and update. Allergy. 2018;73(8):1575‐1596. - PubMed
    1. Bernstein JA. Severity of hereditary angioedema, prevalence, and diagnostic considerations. Am J Manag Care. 2018;24(14 Suppl):S292‐S298. - PubMed
    1. Shire . Highlights of prescribing information. Takhzyro™ (lanadelumab‐flyo) injection, for subcutaneous use. 2018; https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf
    1. Kenniston JA, Faucette RR, Martik D, et al. Inhibition of plasma kallikrein by a highly specific active site blocking antibody. J Biol Chem. 2014;289(34):23596‐23608. - PMC - PubMed
    1. Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108‐2121. - PMC - PubMed

Publication types

MeSH terms

Substances